Research Papers:

Involvement of let-7 microRNA for the therapeutic effects of Rhenium-188-embedded liposomal nanoparticles on orthotopic human head and neck cancer model

Liang-Ting Lin, Chun-Yuan Chang, Chih-Hsien Chang, Hsin-Ell Wang, Shih-Hwa Chiou, Ren-Shyan Liu, Te-Wei Lee and Yi-Jang Lee _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:65782-65796. https://doi.org/10.18632/oncotarget.11666

Metrics: PDF 1639 views  |   HTML 2296 views  |   ?  


Liang-Ting Lin1,2, Chun-Yuan Chang1, Chih-Hsien Chang3, Hsin-Ell Wang1, Shih-Hwa Chiou2,4,5, Ren-Shyan Liu1, Te-Wei Lee3, Yi-Jang Lee1,6

1Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, Taiwan

2Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan

3Isotope Application Division, Institute of Nuclear Energy Research, Taoyuan, Taiwan

4Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan

5Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan

6Biophotonics and Molecular Imaging Research Center (BMIRC), National Yang-Ming University, Taipei, Taiwan

Correspondence to:

Te-Wei Lee, email: [email protected]

Yi-Jang Lee, email: [email protected]

Keywords: 188Re-liposome, HNSCC, orthotopic tumor model, microarray analysis, let-7 microRNA

Received: May 20, 2016     Accepted: August 13, 2016     Published: August 29, 2016


Human head and neck squamous cell carcinoma (HNSCC) is usually treated by surgical resection with adjuvant radio-chemotherapy. In this study, we examined whether the radiopharmaceutical 188Re-liposome could suppress the growth of HNSCC followed by an investigation of molecular mechanisms. The orthotopic HNSCC tumor model was established by human hypopharyngeal FaDu carcinoma cells harboring multiple reporter genes. The drug targeting and therapeutic efficacy of 188Re-liposome were examined using in vivo imaging, bio-distribution, pharmacokinetics, and dosimetry. The results showed that 188Re-liposome significantly accumulated in the tumor lesion compared to free 188Re. The circulation time and tumor targeting of 188Re-liposome were also longer than that of free 188Re in tumor-bearing mice. The tumor growth was suppressed by 188Re-liposome up to three weeks using a single dose treatment. Subsequently, microarray analysis followed by Ingenuity Pathway Analysis (IPA) showed that tumor suppressor let-7 microRNA could be an upstream regulator induced by 188Re-liposome to regulate downstream genes. Additionally, inhibition of let-7i could reduce the effects of 188Re-liposome on suppression of tumor growth, suggesting that let-7 family was involved in 188Re-liposome mediated suppression of tumor growth in vivo. Our data suggest that 188Re-liposome could be a novel strategy for targeting HNSCC partially via induction of let-7 microRNA.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11666